A rare cutaneous infection with Mycobacterium chelonae in a pediatric patient treated with trametinib for KRAS‐mutated diffuse glioma

Mitogen‐activated extracellular signal‐regulated kinase inhibitors (MEKi) represent a promising new therapy for pediatric patients with low‐grade gliomas, which frequently have abnormal signaling within the mitogen‐activated protein kinase (MAP kinase) pathway. However, understanding of long‐term efficacy and toxicity is limited in pediatric glioma patients. This article describes a rare presentation of a widespread cutaneous infection with Mycobacterium chelonae in a pediatric patient with a low‐grade glioma treated with trametinib.